This afternoon we watched DexCom rise 6.0% to a price of $78.77 per share. The Large-Cap Medical Instruments & Supplies company is now trading -22.83% below its average target price of $102.08. Analysts have set target prices ranging from $83.0 to $115.0 per share for DexCom, and have given the stock an average rating of buy.
The stock has an average amount of shares sold short at 3.2%, and a short ratio of 2.7. The company's insiders own 0.42% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 97.5% of DexCom's shares being owned by this investor type.
Institutions Invested in DexCom
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-06-30 | Vanguard Group Inc | 12% | 48,322,405 | $3,806,413,929 |
| 2025-06-30 | Blackrock Inc. | 10% | 39,032,096 | $3,074,605,121 |
| 2025-06-30 | State Street Corporation | 4% | 16,858,078 | $1,327,931,068 |
| 2025-06-30 | BAILLIE GIFFORD & CO | 4% | 16,705,195 | $1,315,888,291 |
| 2025-06-30 | Jennison Associates LLC | 3% | 11,517,546 | $907,250,943 |
| 2025-06-30 | Geode Capital Management, LLC | 3% | 10,766,356 | $848,078,804 |
| 2025-06-30 | Sands Capital Management, LLC | 3% | 9,947,944 | $783,611,507 |
| 2025-06-30 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2% | 9,130,614 | $719,229,440 |
| 2025-06-30 | Nuveen, LLC | 2% | 7,568,890 | $596,210,563 |
| 2025-06-30 | Massachusetts Financial Services Co. | 2% | 6,605,687 | $520,337,905 |
Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on DexCom.
